With a background in clinical and experimental neuropsychology, I am interested in the detection of neurocognitive and brain changes in Alzheimer’s Disease, (AD) which has a preclinical duration of many years before progressive neuronal changes give rise to clear-cut cognitive impairments. We have contributed to establishing Subjective Cognitve Decline as a stage of preclinical AD. Working with psychometric and brain imaging methods, we examine risk and protective factors for AD, including genetic factors, cognitive reserve and lifestyle, including dietary habits and nutrition. Finally, we are involved in clinical interventional trials with sensitive and targeted outcomes, in order to establish treatments for early AD.